Structural and genetic similarities between immunoglobulins and class-1 histocompatibility antigens

Stepping forward in antibody-drug conjugate development

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody, a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the toxic payload to tumor cells. After intravenous administration, ADCs enter circulation, distribute to tumor tissues and bind to the tumor surface antigen. The antigen then undergoes endocytosis to internalize the ADC into tumor cells, where it is transported to lysosomes to release the payload. The released toxic payloads can induce apoptosis through DNA damage or microtubule inhibition and can kill surrounding cancer cells through the bystander effect. The first ADC drug was approved by the United States Food and Drug Administration (FDA) in 2000, but the following decade saw no new approved ADC drugs. From 2011 to 2018, four ADC drugs were approved, while in 2019 and 2020 five more ADCs entered the market. This demonstrates an increasing trend for the clinical development of ADCs. This review summarizes the recent clinical research, with a specific focus on how the in vivo processing of ADCs influences their design. We aim to provide comprehensive information about current ADCs to facilitate future development.

Natural killer and T-cell potentiation by monoclonal IgG against natural killer cell FcR(IgG) or the T3 complex

Treatment of human natural killer (NK) cells with monoclonal antibodies of the IgG isotype against NK cell-FcR(IgG) increased lysis of most haematopoietic target cell lines with high or intermediate background NK susceptibility. Treatment of normal non-adherent lymphocytes with an IgG anti-T3 monoclonal antibody also increased lysis against the same target cells. Potentiating anti-FcR antibodies rapidly modulated FcR activity and the capacity of the cells to act as antibody-dependent killers, although such antibodies were demonstrable for a long time at the cell surface. Anti-FcR treatment did not influence concanavalin A (Con A)-dependent killing, in contrast to anti-T3 treatment, which suppressed lectin-dependent lysis but did not influence antibody-dependent killing. The data is compatible with a 'pro-receptor' theory for FcR in NK killing, stating that such receptors may function in the same way as the T3 complex interacts with specific T cell receptors.

Monoclonal antibodies against the NK cell-FcR and the T3-complex potentiate normal lymphocyte killing

Pretreatment of normal human lymphocytes with monoclonal IgG against the NK cell-FcR (IgG) or the T3 complex was found to potentiate killing of most NK sensitive target cells with the exception of T-cell derived cells. Anti-FcR IgM monoclonals were suppressive for all target cells. IgG anti-FcR mediated potentiation required minute amounts of antibody but was also seen at high anti-FcR concentrations that modulated FcR activity. Potentiated and FcR modulated cells retained anti-FcR IgG on the membrane and conjugated normally to target cells. Anti-FcR potentiation blocked antibody-dependent killing but did not influence lectin-dependent killing, with anti-T3 the opposed effect was seen. Combined anti-FcR and anti-T3 treatment resulted in decreased potentiation. The results suggest that the NK cell-FcR may be activated during normal NK cell killing (without the addition of antibody) as suggested for FcR in B cell triggering.

Serological and partial molecular characterization of a Thy-1 homolog in tunicates

The occurrence of a Thy-1 homolog in the tissues of the advanced invertebrate group of tunicates has been investigated by using two monoclonal antibodies specific to rodent Thy-1.1 determinants and a heterologous anti-rat Thy-1 antiserum. In cellular and soluble-phase radioimmunoassays for Thy-1 using intact hemocytes, tissue extracts and hemolymph, membrane-bound and soluble Thy-1.1 cross-reacting determinants have been detected. Immunoprecipitation experiments with hemocyte deoxycholate extracts and hemolymph, labeled with 125I by lactoperoxidase/chloramine T and with NaB3H4 by galactose oxidase, established the association of the Thy-1.1 cross-reacting determinants with a single glycoprotein of apparent m.w. estimated at 27 000 in hemocytes and 22 500 in hemolymph by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The significance of this finding is discussed in relation to the phylogenetic emergence of the Thy-1 molecule during evolution.

Interaction between insulin receptors and major histocompatibility complex antigens in mouse liver membranes

Insulin receptors from H-2k mouse liver membranes were specifically labelled using a photoreactive insulin analogue coupled to the alpha-subunit (Mr 130,000) of the receptor by ultraviolet-irradiation. Up to 25% of the labelled insulin receptors recovered after membrane solubilization and precipitable by anti-insulin receptor antibodies could be immunoprecipitated by various monoclonal antibodies reacting with H-2Kk antigens. None of these monoclonal antibodies inhibited insulin binding to its receptor. These results show that insulin receptors and H-2Kk antigens interact in liver plasma membranes to form non-covalent complexes. This association between insulin receptors and major histocompatibility complex antigens could be involved in the pathogenesis of certain forms of insulin resistance.